• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    BIMI Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq

    4/23/24 4:05:00 PM ET
    $BIMI
    Other Pharmaceuticals
    Health Care
    Get the next $BIMI alert in real time by email

    New York, April 23, 2024 (GLOBE NEWSWIRE) --  BIMI Holdings Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), previously known as BIMI International Medical Inc., a healthcare products and services provider, today announced that on April 19, 2024, it received a delinquency compliance alert notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that due to the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, with the Securities and Exchange Commission (the "SEC"), the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires the timely filing of all required periodic reports with the SEC.

    Nasdaq provided the Company 60 days to submit a plan to regain compliance with the Rule (the "Plan").  The Company intends to submit its plan of compliance to Nasdaq by June 18, 2024. If Nasdaq accepts the Plan, the Company may be granted an extension of 180 calendar days from the due date of the Form 10-K, or until October 14, 2024, to regain compliance with the Rule. In the event the Plan is not accepted by Nasdaq, the Company may appeal that decision to a Hearings Panel.

    About BIMI Holdings Inc.

    BIMI Holdings Inc. is a healthcare products and services provider, offering a broad range of healthcare products and related services in the U.S. and Asia. For more information, please visit usbimi.com.

    Forward-Looking Statements

    This announcement contains forward-looking statements as defined under Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, formulated in accordance with the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. These statements, reflecting the Company's projections about its future financial and operational performance, employ terms like 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'target,' 'aim,' 'predict,' 'outlook,' 'seek,' 'goal,' 'objective,' 'assume,' 'contemplate,' 'continue,' 'positioned,' 'forecast,' 'likely,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately,' and similar expressions to convey the uncertainty of future events or outcomes. These forward-looking statements are based on the Company's current expectations, assumptions, and projections, involving judgments about future economic conditions, competitive landscapes, market dynamics, and business decisions, many of which are inherently challenging to predict accurately and are largely beyond the Company's control. Additionally, these statements are subject to a multitude of known and unknown risks, uncertainties, and other variables that could significantly diverge the Company's actual results from those depicted in any forward-looking statement. These factors include, but are not limited to, varying economic conditions, competitive pressures, and regulatory changes. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

    Investor Relations Contact

    Investor Relations Department of BIMI Holdings Inc.

    Email: [email protected]

    Tel: +1 949 981 6274



    Get the next $BIMI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIMI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIMI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BIMI Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq

      New York, May 20, 2024 (GLOBE NEWSWIRE) -- BIMI Holdings Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), previously known as BIMI International Medical Inc., a healthcare products and services provider, today announced that on May 17, 2024, it received a delinquency compliance alert notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that due to its failure to timely file its Form 10-Q for the period ended March 31, 2024, with the Securities and Exchange Commission (the "SEC"), and because the Company remains delinquent in filing its Form 10-K for the fiscal year ended December 31, 2023, it is not in compliance with Nasdaq's contin

      5/20/24 4:09:46 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • BIMI Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq

      New York, April 23, 2024 (GLOBE NEWSWIRE) --  BIMI Holdings Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), previously known as BIMI International Medical Inc., a healthcare products and services provider, today announced that on April 19, 2024, it received a delinquency compliance alert notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that due to the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, with the Securities and Exchange Commission (the "SEC"), the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (

      4/23/24 4:05:00 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • BIMI Announces Results of 2023 Annual General Meeting of Stockholders

      New York, Jan. 03, 2024 (GLOBE NEWSWIRE) -- BIMI Holdings Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), previously known as (BIMI International Medical Inc.) a healthcare products and services provider, today announced the results of the Company's 2022 Annual General Meeting of Stockholders (the "Annual Meeting") held on Dec 29, 2023 at 11:00 a.m. at the offices of the Company, 725 5th Ave, New York, NY 10022. At the Annual General Meeting the shareholders voted and approved; 1. The election of seven directors to serve on the board of directors of the Company, until the next annual meeting of Stockholders and until their respective successors have been duly elected and quali

      1/3/24 7:00:00 AM ET
      $BIMI
      Other Pharmaceuticals
      Health Care

    $BIMI
    SEC Filings

    See more
    • BIMI International Medical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - BIMI Holdings Inc. (0001213660) (Filer)

      7/29/24 4:01:18 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • BIMI International Medical Inc. filed SEC Form 8-K: Leadership Update

      8-K - BIMI Holdings Inc. (0001213660) (Filer)

      6/4/24 4:30:41 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • BIMI International Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - BIMI Holdings Inc. (0001213660) (Filer)

      5/24/24 4:01:39 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care

    $BIMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Oudom Fnu was granted 1,123,500 shares, increasing direct ownership by 285% to 1,518,243 units (SEC Form 4)

      4 - BIMI Holdings Inc. (0001213660) (Issuer)

      6/13/24 1:06:18 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • New insider Smith Symington Wei claimed ownership of 3,456 shares (SEC Form 3)

      3 - BIMI Holdings Inc. (0001213660) (Issuer)

      3/20/24 8:04:41 AM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • Tiewei Song sold $2,903 worth of shares (724 units at $4.01), decreasing direct ownership by 0.21% to 341,117 units (SEC Form 4)

      4 - BIMI Holdings Inc. (0001213660) (Issuer)

      3/4/24 4:03:12 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care

    $BIMI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by BIMI International Medical Inc. (Amendment)

      SC 13D/A - BIMI Holdings Inc. (0001213660) (Subject)

      1/11/24 4:46:28 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by BIMI International Medical Inc. (Amendment)

      SC 13D/A - BIMI International Medical Inc. (0001213660) (Subject)

      12/19/23 4:01:04 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13D filed by BIMI International Medical Inc.

      SC 13D - BIMI International Medical Inc. (0001213660) (Subject)

      8/8/22 4:45:19 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care

    $BIMI
    Financials

    Live finance-specific insights

    See more
    • BIMI International Medical Inc. Announces Third Quarter 2023 Financial Results

      NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) --  BIMI International Medical Inc. (the "Company"), a leading medical solutions provider, today announced its financial results for the three months and nine months ended September 30, 2023. Revenues for the three months ended September 30, 2023 and 2022 were $2,523,193 and $4,932,479, respectively. Revenues for the nine months ended September 30, 2023 and 2022 were $11,278,496 and $10,476,224, respectively. The revenues of the Zhongshan, Qiangsheng, Eurasia, and Minkang hospitals, that are held for sale, were accounted for separately. Net loss for the three months ended September 30, 2023 and 2022 was $3,134,072 and $3,099,662, respectively, whi

      12/19/23 8:01:00 AM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • BIMI International Medical Inc. Announces Second Quarter 2023 Financial Results

      NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the "Company"), a leading medical solutions provider, today announced its financial results for the three months ended June 30, 2023. The Company reported a significant increase in gross margin underlining the ongoing success of its business strategy and operational effectiveness. Revenues for the six months ended June 30, 2023 and 2022 were $8,755,303 and $5,543,745, respectively. Compared with the same period in 2022, revenue increased by $3,211,558, due to the inclusion of the revenues of Phenix Bio Inc., which was acquired on March 15, 2023. The revenues of the Zhongshan, Qiangsheng, Eurasia, and Minkang h

      11/27/23 8:25:00 AM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • BIMI International Medical Inc. Announces First Quarter 2023 Financial Results

      NEW YORK, May 22, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the "Company"), a leading medical solutions provider, today announced its financial results for the three months ended March 31, 2023. The Company reported a significant decrease in net losses and notable improvements in working capital, underlining the ongoing success of its business strategy and operational effectiveness. Revenues for the three months ended March 31, 2023 and 2022 were $3,197,637 and $2,714,711, respectively. The revenues for the three months ended March 31, 2023 were primarily attributable to the revenues from sales of healthcare products by Phenix Bio Inc., a newly acquired subsidiary, and  fr

      5/22/23 9:25:53 AM ET
      $BIMI
      Other Pharmaceuticals
      Health Care

    $BIMI
    Leadership Updates

    Live Leadership Updates

    See more
    • BIMI Announces Results of 2023 Annual General Meeting of Stockholders

      New York, Jan. 03, 2024 (GLOBE NEWSWIRE) -- BIMI Holdings Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), previously known as (BIMI International Medical Inc.) a healthcare products and services provider, today announced the results of the Company's 2022 Annual General Meeting of Stockholders (the "Annual Meeting") held on Dec 29, 2023 at 11:00 a.m. at the offices of the Company, 725 5th Ave, New York, NY 10022. At the Annual General Meeting the shareholders voted and approved; 1. The election of seven directors to serve on the board of directors of the Company, until the next annual meeting of Stockholders and until their respective successors have been duly elected and quali

      1/3/24 7:00:00 AM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • BIMI International Medical Inc. Announces Subsidiary Phenix Bio Inc's Appointment of Hong Kong, Taiwan, and Macau Exclusive Distributor

      NEW YORK, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ:BIMI, "BIMI"))), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company ("Hao Mu"), as its exclusive distributor responsible for the distribution of Phenix's 17 herbal supplements in Hong Kong, Taiwan and Macau. Pursuant to the terms of a sales agreement entered into on October 29, 2023, Hao Mu must make annual purchases of at least $5 million in order to maintain its exclusive distributor status for this territory. Under the terms of this agreement, Phenix's comprehensive portfolio of high-quality herbal su

      10/30/23 9:29:00 AM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • BIMI International Medical Inc. Announces Subsidiary Phenix Bio Inc's Appointment of Mainland China Non-Exclusive Distributor

      NEW YORK, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ:BIMI, "BIMI"))), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company ("Hao Mu"), as a distributor responsible for the distribution of Phenix's 17 herbal supplements in Mainland China. Pursuant to the terms of a sales agreement entered into on October 29, 2023, Hao Mu must make annual purchases of at least $5 million in order to maintain its distributor status for this territory. Under the terms of this agreement, Phenix's comprehensive portfolio of high-quality herbal supplements will be made available to co

      10/30/23 9:27:00 AM ET
      $BIMI
      Other Pharmaceuticals
      Health Care